A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab

Rectal Cancer Clinical Trial

— FC-4  

Official title:

A Randomized Phase II Clinical Trial Investigating Irinotecan Plus Cetuximab With or Without Anti-Insulin-Like Growth Factor-I Receptor Monoclonal Antibody (IMC-A12) for the Treatment of Patients With Metastatic K-Ras Wild Type Carcinoma of the Colon or Rectum That Has Progressed on Oxaliplatin and Bevacizumab Given as First-Line Therapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00845039
• Other study ID #: 13928
• Secondary ID: CP13-0708I5A-IE-
• Status: Terminated
• Phase: Phase 2
• Start date: May 2009
• Est. completion date: February 2011

Study information

• Verified date: June 2018
• Source: Eli Lilly and Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the value of adding IMC-A12 to irinotecan and cetuximab in participants with metastatic colorectal cancer (CRC).

Description:

The purpose of this study is to determine the value of adding IMC-A12 to irinotecan + cetuximab in improving progression-free survival (PFS) at 18 weeks from the date of randomization for participants with metastatic Kirsten Rat Sarcoma (K-RAS) wild-type CRC that has progressed on an oxaliplatin/bevacizumab-containing regimen.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 4
• Est. completion date: February 2011
• Est. primary completion date: February 2011
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must consent to be in the study and must have signed and dated Institutional Review Board (IRB)-approved consent forms conforming to federal and institutional guidelines for the pre-entry tumor sample submission for central K-RAS testing and for the study treatment

• Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

• Must have metastatic CRC

• The CRC tumor or metastatic tumor must be v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog gene (K-RAS) wild-type as determined by central testing

• Must be documented disease progression during first-line therapy containing both oxaliplatin and bevacizumab

• Most recent treatment regimen must have ended =21 days prior to randomization, and clinically significant side effects associated with previous therapy must have resolved to =Grade 1 with the exception of neuropathy which must have resolved to =Grade 2

• Imaging of the chest, abdomen and pelvis with computed tomography (CT) scan or magnetic resonance imaging (MRI) must be performed within 3 weeks prior to randomization

• Must have measurable disease, defined as at least 1 lesion outside a previous radiation therapy (RT) field that can be accurately measured in at least 1 dimension as =20 millimeters (mm) with conventional techniques or as =10mm with 5mm cuts using a spiral CT scan

• Evidence of adequate bone marrow function: absolute neutrophil (ANC) =1200 cubed millimeters (mm³), hemoglobin =9 grams per deciliter (g/dL), platelets =100,000 mm³

• Evidence of adequate hepatic function. If no liver metastases: aspartate aminotransferase (AST) =2.5 times (x) upper limit of normal (ULN), total bilirubin =1.5 x ULN for the lab. In the presence of liver metastases: AST =5.0 x ULN, total bilirubin =1.5 x ULN for the lab

• Serum creatinine must be =1.5 x ULN for the lab

• Must have a fasting blood glucose <126 milligrams/deciliter (mg/dL). Fasting is defined as no caloric intake for at least 8 hours

Exclusion Criteria:

• Life expectancy less than 12 weeks

• Diagnosis of anal or small bowel carcinoma

• Tumor that is considered by the surgeon to be amenable to complete resection

• Previous RT to >25% of bone marrow

• RT to sites of measurable disease chosen as target lesions

• Radiological evidence and/or clinical signs or symptoms of central nervous system (CNS) metastases

• Any of the following conditions and events: uncontrolled hypertension, defined as systolic blood pressure (BP) >150 millimeters of mercury (mmHg) or diastolic BP >100 mmHg with or without antihypertensive medication (participants with hypertension that is well-controlled on medication are eligible); unstable angina within 6 months before randomization; New York Heart Association (NYHA) Class III or IV cardiac disease; myocardial infarction (MI) within 6 months before randomization; symptomatic arrhythmia; CNS cerebrovascular ischemia [transient ischemic attack (TIA) or stroke] within 6 months before randomization

• Other malignancies unless the participant is considered to be disease-free and has completed therapy for the malignancy =12 months prior to randomization. Participants with the following cancers are eligible if diagnosed and treated within the past 12 months: carcinoma in situ of the cervix, colon carcinoma in situ, melanoma in situ, and basal cell and squamous cell carcinoma of the skin

• Serious or non-healing wound, skin ulcers, or bone fracture

• Any significant bleeding unless the source of bleeding has been resected

• History of bleeding diathesis or coagulopathy (participants on stable anticoagulant therapy are eligible)

• Any evidence of active infection

• Active inflammatory bowel disease

• Grade 3 or 4 diabetes mellitus as defined by National Cancer Institute's (NCI's) Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 pancreatic endocrine: glucose intolerance (participants with diabetes controlled with diet and/or oral medications are eligible)

• Symptomatic interstitial pneumonitis or definitive evidence of interstitial pneumonitis described on CT scan or chest x-ray in asymptomatic participants

• Any other serious concomitant medical condition that, in the opinion of the investigator, would compromise the safety of the participant or compromise the participant's ability to participate in the study

• Previous hypersensitivity reaction to monoclonal antibodies

• Previous treatment with irinotecan, cetuximab, or any agent specifically targeting insulin-like growth factor (IGF) receptors

• Treatment with an investigational drug within 30 days prior to randomization

• Pregnancy or lactation at the time of participant entry

• Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the participant from meeting the study requirements

Related Conditions & MeSH terms

• Colon Cancer
• Rectal Cancer

Intervention

Biological:
• Cetuximab
Cetuximab 500 mg/m² every 14 days until disease progression or participant intolerance

Drug:
• Irinotecan
180 mg/m² every 14 days until disease progression or participant intolerance

Biological:
• IMC-A12 (cixutumumab)
IMC-A12 10 mg/kg every 14 days until disease progression or participant intolerance

Locations

Country	Name	City	State
United States	ImClone Investigational Site	Greenville	North Carolina
United States	ImClone Investigational Site	Scranton	Pennsylvania
United States	ImClone Investigational Site	Vallejo	California

Sponsors (2)

Lead Sponsor	Collaborator
Eli Lilly and Company	NSABP Foundation Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	The Number of Participants Who Died During 30-Day Follow-Up	Reported are the deaths during the 30-day follow-up period regardless of causality.	26.3 months post-randomization up to 30-day post-treatment follow-up
Primary	Progression-Free Survival (PFS) Rate at 18 Weeks		Approximately 18 Weeks
Secondary	Objective Response Rate (ORR) [Complete Response (CR) + Partial Response (PR)]		Randomization up to 26.3 months
Secondary	Overall Survival (OS)		Randomization up to 26.3 months
Secondary	Progression Free Survival (PFS) Over Entire Duration		Randomization up to 26.3 months
Secondary	The Number of Participants Who Had a Complete Resection/Ablation of Metastases With no Evidence of Disease Remaining (Resection Rate)		Randomization up to 26.3 months
Secondary	Toxicity of the Irinotecan + Cetuximab + IMC-A12 Regimen		Randomization up to 26.3 months
Secondary	Post-treatment Serum Levels of IMC-A12 in Participants Receiving IMC-A12		Prior to infusion at Cycles 1, 4, 7 (2-week cycles), and 4 to 6 weeks following discontinuation of treatment IMC-A12 up to 77 weeks
Secondary	Change in Behavioral and Health Outcomes [BAHO] Quality of Life (QoL) Questionnaire		Baseline, after Cycle 3 (14-day cycle), study discontinuation 30-day follow-up (up to 26.3 months)
Secondary	Serum Anti-IMC-A12 Antibody Assessment		Prior to infusion at Cycles 1, 4, 7 (2-week cycles), and 4 to 6 weeks following discontinuation of treatment IMC-A12 up to 77 weeks